Paquinimod

Paquinimod is developed for the treatment of SLE (Systemic Lupus Erythematosus), which is an autoimmune disease. The disease affects mainly women of fertile age and progresses in flares with relatively symptom free periods in between. Current treatments of SLE are NSAID (nonsteroidal anti-inflammatory drugs), corticosteroids, antimalarians or cytotoxic drugs like for example Cyclophosphamide. The autoimmune attack affects several different organ systems and many patients suffer from serious secondary disease symptoms such as renal disorders as the disease progresses.

A mixture of 4 (5.00 g) and N-ethylaniline (4.7 g) in n-heptane (200 mL) was refluxed in a Soxhlet extraction apparatus (Figure 1) containing 4A molecular sieves (22.9 g). The reflux was stopped after 2.0 hours and the mixture was cooled to room temperature. The crystalline suspension was filtered. The precipitate was washed with n-heptane and dried in vacuum to furnish 5.53 g (82 percent) of N-ethyl-N-phenyl-5-ethyl-l, 2-dihydro-4-hydroxy-l-methyl-2-oxo- quinoline-3-carboxamide (A).

Molecular Weight:350.4
XLogP3:3.8
Hydrogen Bond Donor Count:1
Hydrogen Bond Acceptor Count:3
Rotatable Bond Count:4
Exact Mass:350.16304257
Monoisotopic Mass:350.16304257
Topological Polar Surface Area:60.8
Heavy Atom Count:26
Complexity:580
Covalently-Bonded Unit Count:1
Compound Is Canonicalized:Yes